The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells

Improved safety of NCT-50 compared with known Hsp90 inhibitors and

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer

Cancers, Free Full-Text

Enniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancer - ScienceDirect

β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features, Cancer Cell International

HER2-positive MedChemExpress (MCE) Life Science Reagents

Salinomycin decreases the CD44+/CD24- stem-like population during

Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer

Detailed curriculum vitae of HER2-targeted therapy - ScienceDirect

NCT-58 - ZellBio GmbH